Phase I dose-finding study of biweekly oxaliplatin (E) in combination with gemcitabine (G), 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (G-FLIE) in patients with solid tumors.

被引：0
|
作者：
Olszewski, AJ
Malamud, S
Grossbard, ML
Mirzoyev, T
Dietrich, M
Thurakal, A
Rodriguez, T
Kozuch, P
机构：
[1] St Lukes Roosevelt Hosp, New York, NY USA
[2] Beth Israel Med Ctr, New York, NY 10003 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358S / 358S
页数：1
相关论文
共 50 条
  • [1] Phase i study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas
    Olszewski A.J.
    Grossbard M.L.
    Chung M.S.
    Chalasani S.B.
    Malamud S.
    Mirzoyev T.
    Kozuch P.S.
    Journal of Gastrointestinal Cancer, 2013, 44 (2) : 182 - 189
  • [2] Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors
    Rachamalla, R
    Malamud, S
    Grossbard, ML
    Mathew, S
    Dietrich, M
    Kozuch, R
    ANTI-CANCER DRUGS, 2004, 15 (03) : 211 - 217
  • [3] Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors.
    Hegeman, RB
    Mulkerin, D
    Thomas, J
    Alberti, D
    Binger, K
    Marnocha, R
    Kolesar, J
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 149S - 149S
  • [4] A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
    Fisher, GA
    Cho, CD
    Halsey, JZ
    Advani, RH
    Yuen, AR
    Lum, BL
    Sikic, BI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S63 - S63
  • [5] Biweekly irinotecan in combination with gemcitabine (G), 5-fluorouracil (5-FU), leucovorin (LV) and cisplatin (G-FLIP) associated with encouraging activity in patients with metastatic pancreatic cancer: Update of a phase I-II trial.
    Rachamalla, R
    Malamud, S
    Grossbard, ML
    Mathew, S
    Dietrich, M
    Kozuch, PS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 360S - 360S
  • [6] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [7] Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOL-FOX41 in patients with solid tumors.
    Lakhai, WS
    Beijnen, JH
    Den Boer, SS
    Westermann, AM
    Versola, M
    Koch, K
    Ho, P
    Pandite, L
    Richel, DJ
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [8] A dose finding study of biweekly administration of irinotecan (CPT-11), 5-fluorouracil (5-FU) and levofolinic acid (I-LV) in colorectal cancer
    Casaretti, R
    Catalano, G
    Comella, P
    De Vita, F
    Avallone, V
    Gravina, A
    Orditura, M
    Comis, S
    Faranda, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [9] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in previously treated patients with advanced metastatic gastric cancer
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Anselmi, E
    Bidin, L
    Palladino, M
    Rodinò, C
    ANNALS OF ONCOLOGY, 2005, 16 : 323 - 323
  • [10] Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study
    Yang, TS
    Chen, JS
    Tang, R
    Chiang, JM
    Hsieh, PS
    Yeh, CY
    Changchien, CR
    ANTI-CANCER DRUGS, 2003, 14 (02) : 145 - 151
12345